相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
100.0%
暂无批准数据
- The Asia Bio Partnering Forum 2026, held 1–2 September at Marina Bay Sands, framed APAC's shift from a manufacturing base to a region that originates healthcare innovation. - A central question emerged: are biotech companies increasingly valued for data assets, AI capabilities and platform intelligence as much as for their therapeutic pipelines? - Panellists including Bayer, WuXi XDC, CBC Group and AliHealth Hongyun Capital argued that platform premiums matter in early financing, but transaction reality demands tangible value for drug development and patients. - The forum concluded that data is now an asset class, deal structure is a competitive weapon, and global credibility must be designed at protocol stage rather than retrofitted.
- Modicus Prime raised $8 million in total funding, including a recent $4.5 million round led by Frist Cressey Ventures, to expand its AI compliance infrastructure for pharmaceutical companies. - The company's Trustworthy AI Compliance Software integrates with pharmaceutical technology stacks to provide centralized oversight for AI governance across regulated GxP environments globally. - The platform addresses an industry problem estimated at $50 billion annually in quality control failures by enabling audit-ready AI deployment across pharmaceutical organizations. - CEO Taylor Chartier co-authored the ISPE GAMP AI Guide and has been instrumental in shaping industry standards for AI implementation in regulated pharmaceutical environments.
- Ternary Therapeutics raised £3.6 million in seed funding to scale its AI-powered platform for designing molecular glue drugs that force proteins to bind together for therapeutic purposes. - The London-based company combines physics-informed AI, molecular dynamics modeling, and laboratory testing to systematically design molecular glues rather than relying on accidental discovery. - The platform has already generated a preclinical pipeline targeting inflammatory diseases and secured multiple research collaborations with pharmaceutical and biotechnology companies. - Former Arvinas R&D president Dr. Ian Taylor joined Ternary's board, bringing expertise from targeted protein degradation research and six IND submissions during his tenure.
- President Trump's executive order implementing a "Most Favored Nation" pricing policy could slash U.S. drug prices by 30-80%, sending shockwaves through the global pharmaceutical industry. - German pharmaceutical giants like Merck and Bayer face significant threats, with Simon-Kucher consultancy projecting potential 64% drops in U.S. pharmaceutical sales and 37% global declines. - A Deloitte study warns that a 35% U.S. tariff on drug imports could reduce German pharmaceutical exports to the U.S. by 53%, potentially causing industry losses of up to €13.4 billion over 3-4 years.
- The second annual London Biotechnology Show (#LBS25) builds on the success of its inaugural edition, which attracted over 3,000 attendees from 1,500 companies and featured 70+ sponsors and exhibitors. - This year's expanded event features a 4,000 square meter floor plan showcasing cutting-edge products and services from leading companies including Discovery Park, Merck, Microsoft, and AstraZeneca. - The show introduces a Hosted Buyer Programme offering pre-arranged one-to-one meetings to facilitate strategic partnerships and business growth opportunities. - An enhanced conference program will feature speakers from major organizations including Novo Nordisk, Pfizer, Bayer Pharmaceuticals, and the Medicines and Healthcare products Regulatory Agency discussing gene editing, regenerative medicine, and digital health innovations.
- Leading experts from Bayer Pharmaceuticals and IPG Health will convene on March 5th, 2025, to discuss the transformative potential of cell and gene therapies in rare disease treatment. - The webinar will address critical challenges in rare disease therapy development, including small patient populations, limited natural history data, and the complexities of implementing cell and gene therapies. - Healthcare professionals will gain insights into support strategies, treatment barriers, and future opportunities in the expanding field of cell and gene therapy for rare diseases.
- Bayer has initiated clinical investigations into sepsis-associated coagulopathy (Study 22265), addressing a critical area with high mortality rates and limited treatment options. - A separate clinical trial (Study 20732) is exploring novel therapeutic approaches for obstructive sleep apnea, a common sleep disorder affecting millions worldwide. - These trials reflect Bayer's commitment to addressing unmet medical needs across different therapeutic areas, with detailed results expected to inform future treatment guidelines.
- The CDSCO's waiver of local clinical trial requirements for drugs approved in well-regulated markets aims to expedite access to essential medications for Indian patients. - This decision is particularly beneficial for patients with rare diseases and those requiring cell and gene therapies, addressing previously unmet needs. - The waiver allows pharmaceutical companies to focus resources on improving drug access and awareness, rather than duplicating clinical trials. - The move reflects confidence in the regulatory standards of countries like the US, UK, Japan, Australia, Canada, and the EU, fostering quicker access to innovative treatments.
